17Sep/13

Chronic Kidney Disease Drug Gets a Name – Drug Discovery & Development

Chronic Kidney Disease Drug Gets a Name
Drug Discovery & Development
The U.S. Food & Drug Administration (FDA) has accepted the proposed proprietary trade name Triferic for the Rockwell Medical’s investigational iron-delivery drug, previously known as soluble ferric pyrophosphate (SFP), which is intended for treating
Rockwell Medical Announces FDA Acceptance of Triferic(TM) as Proprietary MENAFN.COM
Rockwell Medical Has a 52 Week Low of $3.16 & a 52 Week High of $11.80SBWire (press release)

all 8 news articles »